Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aurinia Pharmaceuticals Inc (AUP.TO)

Aurinia Pharmaceuticals Inc (AUP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2,147,902
  • Shares Outstanding, K 128,396
  • Annual Sales, $ 175,513 K
  • Annual Income, $ -78,020 K
  • 60-Month Beta 0.26
  • Price/Sales 32.26
  • Price/Cash Flow N/A
  • Price/Book 4.67
Trade AUP.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -1.16
  • Most Recent Earnings $-0.37 on N/A
  • Next Earnings Date 08/05/21
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.42
  • Number of Estimates 4
  • High Estimate -0.36
  • Low Estimate -0.46
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.64 +22.87%
on 07/27/21
18.37 -8.76%
on 07/29/21
+0.69 (+4.29%)
since 06/30/21
3-Month
11.77 +42.40%
on 05/11/21
18.37 -8.76%
on 07/29/21
+0.44 (+2.70%)
since 04/30/21
52-Week
11.77 +42.40%
on 05/11/21
26.00 -35.54%
on 01/25/21
-1.21 (-6.73%)
since 07/30/20

Most Recent Stories

More News
Aurinia: Q1 Earnings Snapshot

Aurinia: Q1 Earnings Snapshot

AUP.TO : 16.76 (-3.51%)
Aurinia: Q4 Earnings Snapshot

Aurinia: Q4 Earnings Snapshot

AUP.TO : 16.76 (-3.51%)
Aurinia: Q3 Earnings Snapshot

Aurinia: Q3 Earnings Snapshot

AUP.TO : 16.76 (-3.51%)
Aurinia: Q2 Earnings Snapshot

Aurinia: Q2 Earnings Snapshot

AUP.TO : 16.76 (-3.51%)
Aurinia: Q1 Earnings Snapshot

Aurinia: Q1 Earnings Snapshot

AUP.TO : 16.76 (-3.51%)
Aurinia: Q4 Earnings Snapshot

Aurinia: Q4 Earnings Snapshot

AUP.TO : 16.76 (-3.51%)
Aurinia: Q3 Earnings Snapshot

Aurinia: Q3 Earnings Snapshot

AUP.TO : 16.76 (-3.51%)
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the...

AUP.TO : 16.76 (-3.51%)
AUPH : 7.12 (+1.42%)
Aurinia: Q3 Earnings Snapshot

VICTORIA, British Columbia (AP) _ Aurinia Pharmaceuticals Inc. (AUPH) on Wednesday reported a loss of $50.3 million in its third quarter.

AUP.TO : 16.76 (-3.51%)
U.S. Jobs Figures Due Ahead of Labour Day

Monday U.S. Economic Lookahead Pending home sales (July) Featured Earnings Zoom Video Communications ...

AUP.TO : 16.76 (-3.51%)
ZM : 68.66 (+2.16%)
CTLT : 60.59 (-0.20%)
STNE : 11.33 (+3.19%)
NTES : 102.33 (+0.86%)
PVH : 97.90 (+3.18%)
AMBA : 56.20 (-1.70%)
VEEV : 204.67 (+0.07%)
CHWY : 29.02 (+0.14%)
OKTA : 72.31 (+0.31%)
AVGO : 176.64 (+2.76%)
DOCU : 63.84 (+1.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically,...

See More

Key Turning Points

3rd Resistance Point 18.39
2nd Resistance Point 17.93
1st Resistance Point 17.34
Last Price 16.76
1st Support Level 16.29
2nd Support Level 15.83
3rd Support Level 15.24

See More

52-Week High 26.00
Fibonacci 61.8% 20.56
Fibonacci 50% 18.89
Fibonacci 38.2% 17.21
Last Price 16.76
52-Week Low 11.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar